Róża Przanowska
@rprzanowska.bsky.social
NCI K00 Fellow in Janes Lab at U of Virginia BME (USA) working on ncRNAs in breast cancer. PhD on ncRNAs in myogenesis in Dutta lab at UVA BMG. MSc from U of Warsaw (Poland). Mom of three and wife of Dr. Piotr Przanowski, scientist and HEMA fighter.
Congratulations, Paweł! Great and impactful story.
April 17, 2025 at 12:43 PM
Congratulations, Paweł! Great and impactful story.
Submitting in June and so happy to see the extension!
January 18, 2025 at 1:44 AM
Submitting in June and so happy to see the extension!
One of my favorites! :)
January 18, 2025 at 1:43 AM
One of my favorites! :)
Believe me, I was shocked 😆
January 6, 2025 at 2:53 AM
Believe me, I was shocked 😆
Thank you, Will! Excited to see you soon :)
January 6, 2025 at 2:52 AM
Thank you, Will! Excited to see you soon :)
Thank you! All the best to you!
January 6, 2025 at 2:52 AM
Thank you! All the best to you!
Thank you, Mariusz! :)
January 6, 2025 at 2:51 AM
Thank you, Mariusz! :)
We have not tested it in this model but you may be interested in another preprint from our lab.
In short, MCM2-7 is still loaded at comparable rates in G1 phase to license reserve origins and in the same S phase to permit re-replication in human cancer cell lines lacking ORC.
In short, MCM2-7 is still loaded at comparable rates in G1 phase to license reserve origins and in the same S phase to permit re-replication in human cancer cell lines lacking ORC.
Specific origin selection and excess functional MCM2-7 loading in ORC-deficient cells
The six subunit Origin Recognition Complex (ORC) loads excess MCM2-7 on chromosomes to promote initiation of DNA replication and is believed to be important for origin specification. Mapping of origin...
www.biorxiv.org
January 3, 2025 at 12:32 PM
We have not tested it in this model but you may be interested in another preprint from our lab.
In short, MCM2-7 is still loaded at comparable rates in G1 phase to license reserve origins and in the same S phase to permit re-replication in human cancer cell lines lacking ORC.
In short, MCM2-7 is still loaded at comparable rates in G1 phase to license reserve origins and in the same S phase to permit re-replication in human cancer cell lines lacking ORC.
These findings open new avenues for understanding DNA replication and cellular adaptation, with potential implications for cancer research and regenerative medicine. Grateful to my co-authors and collaborators for their invaluable contributions. Excited to see where this leads! (4/4)
January 1, 2025 at 8:57 PM
These findings open new avenues for understanding DNA replication and cellular adaptation, with potential implications for cancer research and regenerative medicine. Grateful to my co-authors and collaborators for their invaluable contributions. Excited to see where this leads! (4/4)